Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
8 May 2024
| 16:21 | Cryptogenic cirrhosis diffhist +333 Imam Ali Shah talk contribs | ||||
|
|
16:21 | (Upload log) [Edzelco; Imam Ali Shah (4×)] | |||
|
|
16:21 Imam Ali Shah talk contribs uploaded File:Portal-venous phase CT scan of the abdomen and pelvis in Liver Cirrhosis.png | ||||
|
|
16:19 Imam Ali Shah talk contribs uploaded File:Portal-venous phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg | ||||
|
|
16:18 Imam Ali Shah talk contribs uploaded File:Arterial phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg | ||||
|
|
16:17 Imam Ali Shah talk contribs uploaded File:Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg | ||||
|
|
01:53 Edzelco talk contribs uploaded File:LOQTORZI Dosage.png | ||||
| 16:03 | User:Imam Ali Shah diffhist −61 Imam Ali Shah talk contribs | ||||
| N 14:44 | Template:VSRN diffhist +81 Rithish Nimmagadda talk contribs (Created page with "Rithish Nimmagadda,MBBS.[mailto:rithishnvs@gmail.com]") | ||||
|
|
N 14:30 | FRUZAQLA 3 changes history +9,129 [Rithish Nimmagadda (3×)] | |||
|
|
14:30 (cur | prev) +2 Rithish Nimmagadda talk contribs Tag: Visual edit | ||||
|
|
14:25 (cur | prev) +35 Rithish Nimmagadda talk contribs | ||||
| N |
|
14:10 (cur | prev) +9,092 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |indicationType=treatment |indication=FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. |adverseReactions=Most common adverse reactions ( are hypertension, palma...") | |||
|
|
N 14:21 | User:Rithish Nimmagadda 3 changes history +362 [Rithish Nimmagadda (3×)] | |||
|
|
14:21 (cur | prev) −9 Rithish Nimmagadda talk contribs (→Your Name) | ||||
|
|
14:21 (cur | prev) +9 Rithish Nimmagadda talk contribs (→Your Name) | ||||
| N |
|
14:20 (cur | prev) +362 Rithish Nimmagadda talk contribs (Created page with "<nowiki> __NOTOC__ ==Your Name== ''' Rithish Nimmagadda, MBBS Research scholar <br />Contact:945-278-1660 <br /> Email: rithishnvs@gmail.com [mailto:rithishnvs@gmail.com]<br /> ==Current Position== * research scholar (list chapters here)<br /> ==Education== Medical Degree from Kamineni Academy of Medical sciences and research centre , Hyderabad , India") | |||
| N 13:32 | Fruzaqla diffhist +49 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=rithish }}") | ||||
|
|
04:13 | Zuranolone 2 changes history +5,755 [Alen Antony (2×)] | |||
|
|
04:13 (cur | prev) +2,528 Alen Antony talk contribs | ||||
|
|
03:48 (cur | prev) +3,227 Alen Antony talk contribs | ||||
| 01:58 | User:Edzelco diffhist +22 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| 01:55 | Toripalimab-tpzi diffhist +45,965 Edzelco talk contribs | ||||
7 May 2024
|
|
N 20:18 | Zuranolone 2 changes history +1,853 [Alen Antony (2×)] | |||
|
|
20:18 (cur | prev) +1,017 Alen Antony talk contribs | ||||
| N |
|
17:27 (cur | prev) +836 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zuranolone |aOrAn=a |drugClass=gamma-aminobutyric acid (GABA) A receptor positive modulator |indicationType=treatment |indication=postpartum depression (PPD) in adults |hasBlackBoxWarning=Yes |adverseReactions=somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. |blackBoxWarningTitle=Impaired ability to engage in potential hazardous activity |blackBoxWarningBody=Patients are ad...") | |||
|
|
04:14 | User:Archana.vajjala 5 changes history +4 [Archana.vajjala (5×)] | |||
|
|
04:14 (cur | prev) −25 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
|
|
04:09 (cur | prev) −40 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
|
|
03:59 (cur | prev) +26 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
|
|
03:56 (cur | prev) +3 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
|
|
03:56 (cur | prev) +40 Archana.vajjala talk contribs (→Interests) Tag: Visual edit | ||||
| 03:37 | Perfluorhexyloctane diffhist +904 Alen Antony talk contribs | ||||
6 May 2024
| m 08:50 | Non-degenerate nucleotides per response element diffhist +144 Marshallsumter talk contribs (→Tabulation of counts) | ||||
3 May 2024
| N 22:57 | Xacduro- sulbactam and durlobactam diffhist +11,950 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=sulbactam and durlobactam |aOrAn=a |drugClass=co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, |indicationType=treatment |indication=hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acin...") | ||||
|
|
N 19:10 | Perfluorhexyloctane 3 changes history +1,917 [Alen Antony (3×)] | |||
|
|
19:10 (cur | prev) +1,456 Alen Antony talk contribs | ||||
|
|
18:57 (cur | prev) +210 Alen Antony talk contribs | ||||
| N |
|
18:20 (cur | prev) +251 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=perfluorhexyloctane |aOrAn=a |drugClass=semifluorinated alkane |indicationType=treatment |indication=signs and symptoms of dry eye disease (DED). |adverseReactions=blurred vision. }}") | |||
2 May 2024
| N 15:29 | Trofinetide diffhist +74 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=trofinetide }}") | ||||
|
|
N 04:04 | Zavegepant 2 changes history +4,397 [Alen Antony (2×)] | |||
|
|
04:04 (cur | prev) +2,901 Alen Antony talk contribs | ||||
| N |
|
03:29 (cur | prev) +1,496 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=zavegepant |aOrAn=a |drugClass=calcitonin gene-related peptide (CGRP) receptor antagonist. |indicationType=treatment |indication=acute migraine with or without aura in adults. |adverseReactions=taste disorders, nausea, nasal discomfort, and vomiting |fdaLIADAdult=The recommended dose is 10 mg given intranasally as a single spray in one nostril, as needed, with the maximum dosage at 10mg in 24 hours. |contraindic...") | |||